Gilead Sciences (GILD) EBIT Margin (2009 - 2026)

Gilead Sciences (GILD) has reported EBIT Margin for 18 consecutive years, with 37.16% the latest figure, recorded in Q1 2026.

• EBIT Margin for Q1 2026 came in at 37.16%, up 360.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 34.88% (up 627.0% YoY), and the FY2025 annual result was 34.04%, up 2826.0% from the prior year.
• EBIT Margin was 37.16% for Q1 2026 at Gilead Sciences, up from 25.03% in the prior quarter.
• Over five years, EBIT Margin peaked at 42.82% in Q3 2025 and troughed at 64.64% in Q1 2024.
• Average EBIT Margin over 5 years is 24.08%, with a median of 32.4% recorded in 2024.
• Year-over-year, EBIT Margin tumbled 9148 bps in 2024 and surged 9820 bps in 2025.
• Over 5 years, EBIT Margin stood at 30.68% in 2022, then declined by 26 bps to 22.66% in 2023, then surged by 43 bps to 32.4% in 2024, then retreated by 23 bps to 25.03% in 2025, then jumped by 48 bps to 37.16% in 2026.
• Per Business Quant data, the three most recent EBIT Margin figures were 37.16% in Q1 2026, 25.03% in Q4 2025, and 42.82% in Q3 2025.